ÖGGH Consensus Recasts Primary Biliary Cholangitis Care Around Biochemical Normalization
Primary biliary cholangitis has long been treated as a disease of slow accumulation: persistent cholestasis, progressive bile duct injury, and years of smoldering inflammation before cirrhosis becomes unavoidable. The Austrian Society of Gastroenterology and Hepatology consensus places that process on firmer clinical ground by defining a practical treatment strategy for primary biliary cholangitis centered on earlier biochemical control and tighter follow-up. The document frames PBC as a chronic, autoimmune-mediated disorder of the intrahepatic bile ducts that disproportionately affects middle-aged women and can advance to fibrosis and cirrhosis when cholestatic injury continues unchecked.
PBC is not a silent laboratory curiosity. It is a disease in which persistent elevation of cholestatic enzymes reflects ongoing bile duct damage, and each month of incomplete response leaves less margin for reversal. The consensus treats the biochemical profile as the main bedside signal of whether therapy is suppressing the injury that drives long-term loss of hepatic reserve.
Diagnosis Relies on Cholestatic Enzymes and Disease-Specific Autoantibodies
Diagnosis rests on a cholestatic enzyme pattern together with anti-mitochondrial antibodies or PBC-specific antinuclear antibodies, including sp100 and gp210. In routine practice, that combination is usually sufficient, which keeps the diagnostic pathway focused and avoids unnecessary procedural escalation. Liver biopsy remains uncommon, reserved for selected situations such as suspected PBC-autoimmune hepatitis overlap syndrome or the absence of the characteristic antibodies.
That approach fits the biology of the disease. PBC is classified as an autoimmune liver disease because the immune system targets the intrahepatic bile ducts, but the pathogenesis is still not fully understood. Genetic predisposition and environmental factors appear to interact, and the consensus does not force certainty where the evidence is incomplete. Instead, it organizes care around what can be measured reliably in clinic: cholestatic biochemistry, autoantibody status, symptoms, and response to treatment.
UDCA Remains First-Line Therapy, but Response Targets Have Tightened
First-line treatment remains ursodeoxycholic acid, which achieves clinical and biochemical remission in about 60% to 70% of patients. That figure matters because it defines the size of the group for whom standard therapy is enough and the larger group that will need escalation if the disease continues to smolder. The consensus does not move away from UDCA; it sharpens the standard for judging whether the drug has done enough.
The treatment goal has shifted from meeting predefined response criteria alone to aiming for normalization of alkaline phosphatase together with a low-normal bilirubin level. In practical terms, that change reflects a more aggressive attempt to extinguish residual cholestatic injury rather than simply declare partial success. Normalization of alkaline phosphatase is not an abstract laboratory preference. It is the closest routine marker clinicians have for whether the biliary inflammation that defines PBC is being adequately suppressed.
Bilirubin carries additional weight because low-normal levels have been associated with improved outcomes in some subgroups. The consensus therefore frames bilirubin not as a late-stage bystander but as part of the therapeutic target from the start. When cholestasis persists above these levels, the liver is not fully protected even if symptoms are modest and transaminases are not strikingly abnormal.
Second-Line Therapy Favors Combination Treatment When UDCA Falls Short
Patients who do not respond sufficiently to UDCA should not remain on undertreated monotherapy by default. The consensus recommends combination treatment with UDCA and the newly approved peroxisome proliferator-activated receptor agonists elafibranor and seladelpar, with bezafibrate used off-label where appropriate. The mechanistic logic is straightforward: if bile acid handling and inflammatory signaling remain dysregulated under UDCA alone, adding an agent that acts through a different nuclear receptor pathway offers a stronger chance of biochemical control.
This is where treatment strategy becomes clinically consequential. A patient whose alkaline phosphatase remains elevated after UDCA is not merely “partially controlled”; the disease biology is still active enough to justify escalation. Combination therapy is designed to push the liver toward biochemical remission before fibrosis becomes fixed and portal hypertension enters the picture.
The consensus favors combination use rather than a vague stepwise delay because the disease course rewards earlier suppression of cholestatic injury. Waiting for more overt structural injury does not create a better opportunity for therapy. It only narrows the window in which biochemical improvement can translate into durable clinical benefit.
Cirrhosis and Transplantation Mark the End of Medical Containment
When PBC progresses to decompensated cirrhosis, liver transplantation remains the definitive option and is associated with good long-term outcomes. The post-transplant story is not entirely resolved, however, because disease recurrence occurs in up to 50% of patients by 15 years. That recurrence rate keeps the autoimmune biology relevant even after the diseased liver has been replaced.
The transplant data carry a hard edge. Surgical rescue can restore hepatic function, but it does not erase the immunologic tendency that produced the original disease. Long-term surveillance therefore remains necessary, even after a successful transplant course, because recurrence is common enough to shape counseling and follow-up planning.
Practical Implications for Hepatology Clinics
For hepatology practices, the consensus offers a clear operational message: diagnose PBC with cholestatic enzymes and appropriate autoantibodies, start UDCA promptly, and do not settle for incomplete biochemical response if alkaline phosphatase remains elevated or bilirubin fails to normalize. Symptoms matter, but the disease is governed by the pace of cholestatic injury, not by symptom burden alone.
The document also reinforces how PBC care has changed. Older treatment logic relied heavily on whether patients crossed a predefined response threshold. Current management is more biologically exacting, because the aim is to suppress the injury signal itself until the laboratory profile resembles the least active state achievable in routine care. For many patients, that means combination therapy rather than prolonged reliance on a partial response.
The remaining uncertainty is not whether PBC can be recognized and treated, but how early intensification should be applied in individual patients and how best to preserve long-term liver function once response begins to lag. The consensus provides a structured framework for that decision-making, anchored to measurable biochemical targets and the realities of an autoimmune cholestatic disease that still carries a substantial risk of progression when treatment is incomplete.